Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Melanoma 13Colorectal Neoplasms 5Neoplasm Metastasis 4Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Solid Tumors Harboring a BRAF V600 Mutation 1Skin Neoplasms 1Skin Diseases 1Pancreatic Neoplasms 1Lymphatic Metastasis 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Astrocytoma 1Advanced BRAF Mutant Cancers 1

Interventions

Carboplatin 106Pemetrexed 74Paclitaxel 58Cisplatin 52Erlotinib Hydrochloride 51Radiotherapy 49Docetaxel 43Gemcitabine 41Bevacizumab 41pembrolizumab 30Nivolumab 25Radiosurgery 21Etoposide 20durvalumab 13Cetuximab 13Specimen Handling 12Ipilimumab 12Magnetic Resonance Spectroscopy 11Gefitinib 11Vinorelbine 10Taxes 10Radiation 10Albumin-Bound Paclitaxel 10osimertinib 9Biopsy 9vandetanib 8Topotecan 7Platinum 7Irinotecan 7Drug Therapy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lung Neoplasms × encorafenib × Clear all
NCT03915951 2026-03-24

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Pfizer

Phase 2 Completed
98 enrolled 18 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04585815 2026-01-09

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Pfizer

Phase 1/2 Terminated
34 enrolled 44 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡